DEF 14A: Protagenic Therapeutics Seeks Stockholder Approval for Option Repricing, Warrant Issuance, and Plan Amendment at Upcoming Annual Meeting

Protagenic Therapeutics is holding a virtual annual meeting on February 21, 2025, to vote on key proposals including director elections, option repricing, warrant issuance approval, and an equity incentive plan amendment.

Summary

• Protagenic Therapeutics is holding its virtual Annual Meeting of Stockholders on February 21, 2025, at 10:00 a.m. Eastern Time.
• Stockholders of record as of January 3, 2025, are entitled to vote on several key proposals.
• The proposals include the election of Class III directors, approval of repricing certain stock options, ratification of MaloneBailey, LLP as the independent auditor, approval of common stock warrant share issuance, and an amendment to the 2016 Equity Incentive Plan.
• The Board recommends voting FOR all proposals.
• The company had 7,143,318 outstanding shares of common stock as of the record date.
• The meeting will be accessible online at www.virtualshareholdermeeting.com/PTIX2024.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily presenting information for stockholder voting. While it addresses challenges like stock price decline and the need for option repricing, it also expresses optimism about future prospects. The sentiment is therefore moderately neutral.

Positives

• The virtual meeting format increases stockholder accessibility and participation.
• The proposed repricing of stock options aims to improve employee retention and align employee interests with those of stockholders.
• The company believes that equity compensation is key to linking pay to performance as it encourages employees and executive officers to work toward the company's success.
• The company is seeking to eliminate the need for shareholder approval for repricing stock options, which takes time and costs money to coordinate.

Negatives

• Approval of the warrant issuance could lead to dilution of existing shareholders' ownership interests.
• If the Common Stock Warrants cannot be exercised, the company will not receive proceeds of approximately $2.49 million, which could adversely impact the ability to fund operations.
• The trading price of the company's common stock has significantly declined since the announcement of single-dose Phase I safety results on May 22, 2024.
• As of January 2, 2025, 100% of the company's total outstanding stock options and 100% of the outstanding stock options granted under 2016 Plan are underwater.

Risks

• Failure to obtain stockholder approval for the warrant issuance could result in additional costs and expenses for the company.
• The market price for the company's common stock has historically been volatile, reflecting the risks and uncertainties inherent in the development of product candidates.
• The company faces significant competition for experienced and talented personnel with critical and high demand skills in the industry.
• The company's stock price remains depressed.

Future Outlook

The company remains optimistic regarding the potential of PT-00114, despite the depressed stock price.

Industry Context

As a clinical-stage biopharmaceutical company, the market price for our common stock has historically been volatile, reflecting the risks and uncertainties inherent in the development of product candidates.

Related Party Transactions

• Garo H. Armen and Khalil Barrage invested $200,000 each in the 2019-2020 Convertible Note Offering on the same terms as all other Investors.
• Zack Armen, the son of Executive Chairman Garo H. Armen, assisted with slide deck presentations and summaries, video editing, and forecasting and market size projections and was issued stock options in consideration for his services.

Stakeholder Impact

• Approval of the proposals could impact shareholders through potential dilution and changes in equity compensation.
• Employees and executive officers could benefit from the repricing of stock options.
• The company's ability to fund operations could be affected by the approval or disapproval of the warrant issuance.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on February 21, 2025.
• The Board will determine the Repricing Date for the Eligible Options following the Annual Meeting, if Proposal No. 2 is approved.
• The company will seek shareholder approval every 60 days until shareholders approve the issuance of shares underlying the Common Stock Warrants.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, stock options, repricing, warrants, equity incentive plan, directors, MaloneBailey, corporate governance